Table 4.

Grade 3–4 acute adverse events in 272 patients with stage III NPC

Variables	IMRT (N = 82)	CCRT (N = 190)	P
Hematological
Leukopenia	1 (1.2%)	22 (11.6%)	0.005
Neutropenia	0 (0.0%)	14 (7.4%)	0.012
Anemia	0 (0.0%)	4 (2.1%)	0.186
Thrombocytopenia	0 (0.0%)	9 (4.8%)	0.045
Non-hematological
Mucositis	16 (19.5%)	96 (50.5%)	< 0.001
Xerostomia	0 (0.0%)	4 (2.1%)	0.186
Dermatitis	3 (3.7)	6 (3.2%)	0.833
Nausea/vomiting	0 (0.0%)	5 (2.6%)	0.139
Hepatoxicity	1 (1.2%)	0 (0.0%)	0.128

NPC, nasopharyngeal carcinoma; IMRT, intensity-modulated radiation therapy; CCRT, concurrent chemoradiotherapy